Societal CDMO (SCTL) 10-Q 9 Nov 21 2021 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2021	Nov. 02, 2021
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q3
Entity Registrant Name	Recro Pharma, Inc.
Entity Central Index Key	0001588972
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding		46,614,535
Entity Shell Company	false
Entity Small Business	true
Entity Emerging Growth Company	false
Trading Symbol	REPH
Entity File Number	001-36329
Entity Tax Identification Number	26-1523233
Entity Address, Address Line One	1 E. Uwchlan Ave, Suite 112
Entity Address, City or Town	Exton
Entity Address, State or Province	PA
Entity Address, Postal Zip Code	19341
City Area Code	770
Local Phone Number	534-8239
Entity Incorporation, State or Country Code	PA
Document Quarterly Report	true
Document Transition Report	false
Security Exchange Name	NASDAQ
Title of 12(b) Security	Common Stock, par value $0.01

Consolidated Balance Sheets (Un

Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 23,490	$ 23,760
Accounts receivable	13,746	9,033
Contract asset	7,314	7,330
Inventory	9,440	11,612
Prepaid expenses and other current assets	2,101	2,334
Total current assets	56,091	54,069
Property, plant and equipment, net	50,021	43,841
Operating lease asset	5,963	486
Intangible assets, net	5,993	700
Goodwill	39,568	4,319
Other assets	146
Total assets	157,782	103,415
Current liabilities:
Accounts payable	1,916	1,804
Current portion of debt		1,474
Current portion of related party debt	2,039
Current portion of operating lease liability	1,049	145
Accrued expenses and other current liabilities	7,856	4,380
Total current liabilities	12,860	7,803
Debt, net	91,029	108,097
Related party debt, net of current portion	3,259
Operating lease liability, net of current portion	4,947	366
Other liabilities	1,203	1,249
Total liabilities	113,298	117,515
Commitments and contingencies (note 8)
Shareholders’ deficit:
Preferred stock, $0.01 par value. 10,000,000 shares authorized, none issued or outstanding
Common stock, $0.01 par value. 50,000,000 shares authorized, 31,013,319 and 28,601,358 shares issued and outstanding at March 31, 2021 and December 31, 2020, respectively	466	286
Additional paid-in capital	287,415	219,998
Accumulated deficit	(243,397)	(234,384)
Total shareholders equity (deficit)	44,484	(14,100)
Total liabilities and shareholders equity (deficit)	$ 157,782	$ 103,415

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) (Unaudited) - $ / shares	Sep. 30, 2021	Dec. 31, 2020
Statement Of Financial Position [Abstract]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	95,000,000	95,000,000
Common stock, shares issued	46,614,535	28,601,358
Common stock, shares outstanding	46,614,535	28,601,358

Consolidated Statements of Oper

Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Income Statement [Abstract]
Revenue	$ 18,237	$ 19,287	$ 53,057	$ 56,586
Operating expenses:
Cost of sales (excluding amortization of intangible assets)	13,160	11,741	39,831	41,629
Selling, general and administrative	4,606	4,418	13,076	14,123
Amortization of intangible assets	135	646	835	1,938
Total operating expenses	17,901	16,805	53,742	57,690
Operating income (loss)	336	2,482	(685)	(1,104)
Interest expense	(3,822)	(4,609)	(11,680)	(14,727)
Gain on extinguishment of debt			3,352
Net income (loss)	$ (3,486)	$ (2,127)	$ (9,013)	$ (15,831)
Income (Loss) per share, basic and diluted	$ (0.07)	$ (0.09)	$ (0.22)	$ (0.67)
Weighted average common shares outstanding, basic	51,416,388	23,641,973	40,137,069	23,538,378
Weighted average common shares outstanding, diluted	51,416,388	23,641,973	40,137,069	23,538,378

Consolidated Statements of Shar

Consolidated Statements of Shareholders' Deficit (Unaudited) - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid in Capital [Member]	Accumulated Deficit [Member]
Balance at Dec. 31, 2019	$ (6,712)	$ 233	$ 199,938	$ (206,883)
Balance, Shares at Dec. 31, 2019		23,312,928
Stock-based compensation expense	3,231		3,231
Exercise of stock options, net	(105)		(105)
Exercise of stock options, net, Shares		37,063
Vesting of restricted stock units, net	(916)	$ 1	(917)
Vesting of restricted stock units, net, Shares		105,242
Net income (loss)	(7,692)			(7,692)
Balance at Mar. 31, 2020	(12,194)	$ 234	202,147	(214,575)
Balance, Shares at Mar. 31, 2020		23,455,233
Balance at Dec. 31, 2019	(6,712)	$ 233	199,938	(206,883)
Balance, Shares at Dec. 31, 2019		23,312,928
Net income (loss)	(15,831)
Balance at Sep. 30, 2020	(15,133)	$ 236	207,345	(222,714)
Balance, Shares at Sep. 30, 2020		23,644,631
Balance at Mar. 31, 2020	(12,194)	$ 234	202,147	(214,575)
Balance, Shares at Mar. 31, 2020		23,455,233
Stock-based compensation expense	2,446		2,446
Exercise of stock options, net	379	$ 1	378
Exercise of stock options, net, Shares		105,606
Vesting of restricted stock units, net	(30)	$ 1	(31)
Vesting of restricted stock units, net, Shares		78,067
Net income (loss)	(6,012)			(6,012)
Balance at Jun. 30, 2020	(15,411)	$ 236	204,940	(220,587)
Balance, Shares at Jun. 30, 2020		23,638,906
Stock-based compensation expense	2,409		2,409
Vesting of restricted stock units, net	(4)		(4)
Vesting of restricted stock units, net, Shares		5,725
Net income (loss)	(2,127)			(2,127)
Balance at Sep. 30, 2020	(15,133)	$ 236	207,345	(222,714)
Balance, Shares at Sep. 30, 2020		23,644,631
Balance at Dec. 31, 2020	(14,100)	$ 286	219,998	(234,384)
Balance, Shares at Dec. 31, 2020		28,601,358
Issuance of common stock, net of costs	9,340	$ 22	9,318
Issuance of common stock, net of costs, Shares		2,202,420
Stock-based compensation expense	3,133		3,133
Vesting of restricted stock units, net	(336)	$ 2	(338)
Vesting of restricted stock units, net, Shares		209,541
Net income (loss)	(6,761)			(6,761)
Balance at Mar. 31, 2021	(8,724)	$ 310	232,111	(241,145)
Balance, Shares at Mar. 31, 2021		31,013,319
Balance at Dec. 31, 2020	(14,100)	$ 286	219,998	(234,384)
Balance, Shares at Dec. 31, 2020		28,601,358
Balance at Jun. 30, 2021	26,416	$ 465	265,862	(239,911)
Balance, Shares at Jun. 30, 2021		46,501,849
Balance at Dec. 31, 2020	$ (14,100)	$ 286	219,998	(234,384)
Balance, Shares at Dec. 31, 2020		28,601,358
Exercise of stock options, net, Shares	80
Net income (loss)	$ (9,013)
Balance at Sep. 30, 2021	44,484	$ 466	287,415	(243,397)
Balance, Shares at Sep. 30, 2021		46,614,535
Balance at Mar. 31, 2021	(8,724)	$ 310	232,111	(241,145)
Balance, Shares at Mar. 31, 2021		31,013,319
Issuance of common stock, net of costs	32,103	$ 153	31,950
Issuance of common stock, net of costs, Shares		15,333,332
Stock-based compensation expense	1,929		1,929
Vesting of restricted stock units, net	(126)	$ 2	(128)
Vesting of restricted stock units, net, Shares		155,198
Net income (loss)	1,234			1,234
Balance at Jun. 30, 2021	26,416	$ 465	265,862	(239,911)
Balance, Shares at Jun. 30, 2021		46,501,849
Issuance of common stock, net of costs	20,328		20,328
Stock-based compensation expense	1,319		1,319
Exercise of stock options, net, Shares		80
Vesting of restricted stock units, net	(93)	$ 1	(94)
Vesting of restricted stock units, net, Shares		112,606
Net income (loss)	(3,486)			(3,486)
Balance at Sep. 30, 2021	$ 44,484	$ 466	$ 287,415	$ (243,397)
Balance, Shares at Sep. 30, 2021		46,614,535

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Cash flows from operating activities, continuing operations:
Net loss	$ (9,013)	$ (15,831)
Adjustments to reconcile net loss to net cash provided by operating activities, continuing operations:
Stock-based compensation expense	6,381	8,086
Non-cash interest expense	4,531	4,222
Depreciation expense	4,803	4,581
Amortization of intangible assets	835	1,938
Gain on extinguishment of debt	(3,352)
Changes in operating assets and liabilities:
Accounts receivable	(3,801)	755
Contract asset	521	(877)
Inventory	2,857	3,492
Prepaid expenses and other assets	(491)	268
Accounts payable, accrued expenses and other liabilities	2,162	(234)
Net cash provided by operating activities, continuing operations	6,415	6,400
Cash flows from investing activities:
Acquisition of IriSys, net of cash acquired	(24,006)
Purchases of property and equipment	(2,765)	(5,451)
Net cash used in investing activities	(26,771)	(5,451)
Cash flows from financing activities:
Proceeds from issuance of common stock, net of costs	32,103
Proceeds from issuance of debt		4,416
Repayments of debt	(10,100)	(1,100)
Payment of financing costs	(1,362)	(78)
Net payments related to vesting of restricted stock units	(555)	(1,185)
Net proceeds related to exercise of stock options		509
Net cash provided by financing activities	20,086	2,562
Net (decrease) increase in cash and cash equivalents from continuing operations	(270)	3,511
Cash flows used in discontinued operating activities		(1,172)
Cash and cash equivalents, beginning of period	23,760	19,148
Cash and cash equivalents, end of period	23,490	21,487
Supplemental disclosures of cash flow information:
Cash paid for interest	7,462	10,662
Purchases of property, plant and equipment included in accrued expenses and accounts payable	158	$ 686
Fair value of shares issuable to former equity holders of IriSys	20,931
Fair value of note issued to former equity holder of IriSys	5,240
Receivable from Irisys sellers for net working capital adjustment	6,060
Issuance of common stock to reduce debt principal and accrued exit fees	$ 3,211

Background

Background	9 Months Ended
	Sep. 30, 2021
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Background	(1)   Background Recro Pharma, Inc. (the “Company”) was incorporated in the Commonwealth of Pennsylvania on November 15, 2007 . The Company is a dedicated contract development and manufacturing organization dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development. The Company leverages its formulation and development expertise to develop and manufacture pharmaceutical products using proprietary delivery technologies and know-how for partners who develop and commercialize or plan to commercialize these products. The Company operates in one segment. The Company has incurred net losses since inception and has an accumulated deficit of $ 243,397 as of September 30, 2021 , which is primarily related to the activities of its former research and development business, which was spun-out in 2019. The Company’s future operations are highly dependent on the continued profitability of its manufacturing operations. Management believes that it is probable that the Company will be able to meet its obligations as they become due within at least one year after the date financial statements included herein are issued.

Summary of Significant Accounti

Summary of Significant Accounting Principles	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Summary of Significant Accounting Principles	(2)   Summary of significant accounting principles Basis of presentation and principles of consolidation The accompanying unaudited consolidated financial statements of the Company and its subsidiaries have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information. In accordance with Securities and Exchange Commission ("SEC") rules for interim financial statements, certain information required by U.S. GAAP may be condensed or omitted. The Company’s consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated. In the opinion of management, the accompanying consolidated financial statements include all normal and recurring adjustments (which consist primarily of accruals, estimates and assumptions that impact the financial statements) considered necessary to present fairly the Company’s results for the interim periods. Operating results for interim periods are not necessarily indicative of the results that may be expected for the full year. The accompanying unaudited interim consolidated financial statements should be read in conjunction with the annual audited financial statements and related notes included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020. Use of estimates The preparation of financial statements and the notes to the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from such estimates. Business combinations The Company measures the purchase price paid for acquired companies based on fair value and allocates that purchase price to the assets acquired and liabilities assumed based on their estimated fair values. Valuations are performed to assist in determining the fair values of assets acquired and liabilities assumed, which requires management to make estimates and assumptions, in particular with respect to intangible assets. Management makes estimates of fair value based upon assumptions believed to be reasonable. These estimates are based in part on historical experience and information obtained from the acquired companies and expectations of future cash flows. Costs associated with the transaction are expensed as incurred as selling, general and administrative expenses. Cash and cash equivalents Cash and cash equivalents represent cash in banks and highly liquid short-term investments that have maturities of three months or less when acquired. These highly liquid short-term investments are both readily convertible to known amounts of cash and so near to their maturity that they present insignificant risk of changes in value due to changes in interest rates. Property, plant and equipment Property, plant and equipment are recorded at cost less accumulated depreciation and amortization. Depreciation and amortization are computed using the straight-line method over the estimated useful lives of the assets, which are as follows: three to ten years for furniture, office and computer equipment; six to ten years for manufacturing equipment; 40 years for buildings; and the shorter of the lease term or useful life for leasehold improvements. Repairs and maintenance costs are expensed as incurred. The Company reviews the carrying value of property, plant and equipment for recoverability whenever events occur or changes in circumstances indicate that the carrying amount of individual assets or asset groups may not be recoverable. Goodwill and intangible assets Goodwill represents the excess of purchase price over the fair value of net assets acquired by the Company. Goodwill is not amortized but assessed for impairment on an annual basis or more frequently if impairment indicators exist. The impairment analysis for goodwill consists of an optional qualitative assessment potentially followed by a quantitative analysis. If the Company determines that the carrying value of its reporting unit exceeds its fair value, an impairment charge is recorded for the excess. The Company performs its annual goodwill impairment test as of November 30 th , or whenever an event or change in circumstance occurs that would require reassessment of the recoverability of goodwill. In performing the evaluation, the Company assesses qualitative factors such as overall financial performance, anticipated changes in industry and market conditions, and competitive environments. Definite-lived intangible assets are amortized on a straight-line basis over their estimated useful life. The Company is required to review the carrying value of definite-lived intangible assets for recoverability whenever events occur or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable. Revenue recognition The Company generates revenues from manufacturing, packaging, research and development and related services for multiple pharmaceutical companies. Manufacturing Manufacturing and other related services revenue is recognized upon transfer of control of a product to a customer, generally upon shipment, based on a transaction price that reflects the consideration the Company expects to be entitled to as specified in the agreement with the commercial partner, which could include pricing and volume-based adjustments. Profit-sharing In addition to manufacturing and packaging revenue, certain customer agreements may have intellectual property sales-based profit-sharing and/or royalties consideration, collectively referred to as profit-sharing, computed on the net product sales of the commercial partner. Profit-sharing revenues are generally recognized under the terms of the applicable license, development and/or supply agreement. For arrangements that include sales-based profit-sharing where the license for intellectual property is deemed to be the predominant item to which the profit-sharing relates, the Company recognizes revenue when the related sales occur by the commercial partner. For arrangements that include sales-based profit-sharing where the license for intellectual property is not deemed to be the predominant item to which the profit-sharing relates, the Company recognizes revenue upon transfer of control of the manufactured product. In these cases, significant judgment is required to calculate the estimated variable consideration from such profit-sharing using the expected value method based on historical commercial partner pricing and deductions. Estimated variable consideration is partially constrained due to the uncertainty of price adjustments made by the Company’s commercial partners, which are outside of the Company’s control. Factors causing price adjustments by the Company’s commercial partners include increased competition in the products’ markets, mix of volume between the commercial partners’ customers, and changes in government pricing. Research and development Research and development revenue includes services associated with formulation, process development, clinical trials materials services, as well as custom development of manufacturing processes and analytical methods for a customer’s non-clinical, clinical and commercial products. Such revenues are recognized at a point in time or over time depending on the nature and particular facts and circumstances associated with the contract terms. In contracts that specify milestones, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. Milestone payments related to arrangements under which the Company has continuing performance obligations are deferred and recognized over the period of performance. Milestone payments that are not within the Company’s control, such as submission for approval to regulators by a commercial partner or approvals from regulators, are not considered probable of being achieved until those submissions are submitted by the customer or approvals are received. In contracts that require revenue recognition over time, the Company utilizes input or output methods, depending on the specifics of the contract, that compare the cumulative work-in-process to date to the most current estimates for the entire performance obligation. Under these contracts, the customer typically owns the product details and process, which have no alternative use. These projects are customized to each customer to meet its specifications and typically only one performance obligation is included. Each project represents a distinct service that is sold separately and has stand-alone value to the customer. The customer also retains control of its product as the product is being created or enhanced by the Company’s services and can make changes to its process or specifications upon request. Concentration of credit risk Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash, cash equivalents and accounts receivable. The Company manages its cash and cash equivalents based on established guidelines relative to diversification and maturities to maintain safety and liquidity. The Company’s accounts receivable balances are primarily concentrated among three customers. If any of these customers’ receivable balances should be deemed uncollectible, it could have a material adverse effect on the Company’s results of operations and financial condition. The Company is dependent on its relationships with a small number of commercial partners. The Company's three largest customers generated 81 % and 88 % of its revenues for the three and nine months ended September 30, 2021, respectively. Stock-based compensation expense The Company measures employee stock-based awards at grant-date fair value and recognizes employee compensation expense on a straight-line basis over the vesting period of the award. The Company accounts for forfeitures as they occur. Determining the appropriate fair value of stock options requires the input of subjective assumptions, including the expected life of the option and expected stock price volatility. The Company uses the Black-Scholes option pricing model to value its stock option awards. The assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. As a result, if factors change and/or management uses different assumptions, stock-based compensation expense could be materially different for future awards. The expected life of stock options was estimated using the “simplified method,” which is based on the average of the vesting tranches and the contractual life of each grant. For stock price volatility, the Company uses the historical volatility of its publicly traded stock in order to estimate future stock price trends. The risk-free interest rate is based on U.S. Treasury notes with a term approximating the expected life of the option. Upon exercise of stock options or vesting of restricted stock units, the holder may elect to cover tax withholdings by forfeiting shares of an equivalent value. In such cases, the Company issues net new shares to the holder, pays the tax withholding on behalf of the participant and presents the payment similar to a capital distribution: a reduction to additional paid-in-capital and a financing cash outflow in the consolidated financial statements. For non-employee stock-based awards, the Company recognizes compensation expense on a straight-line basis over the vesting period of each separated vesting tranche of the award, which is known as the accelerated attribution method. The estimation of the number of stock awards that will ultimately vest requires judgment, and to the extent actual results or updated estimates differ from the Company’s current estimates, such amounts are recognized as an adjustment in the period in which estimates are revised. Income taxes Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis, operating losses and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. A valuation allowance is recorded to the extent it is more likely than not that some portion or all of the deferred tax assets will not be realized. A full valuation allowance was recorded as of September 30, 2021 and December 31, 2020. Unrecognized income tax benefits represent income tax positions taken on income tax returns that have not been recognized in the consolidated financial statements. The Company recognizes the benefit of an income tax position only if it is more likely than not (greater than 50%) that the tax position will be sustained upon tax examination, based solely on the technical merits of the tax position. Otherwise, no benefit is recognized. The tax benefits recognized are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. The Company does not anticipate significant changes in the amount of unrecognized income tax benefits over the next year. Income or loss per share Basic income or loss per share is determined by dividing net income or loss (the numerator) by the weighted average common shares outstanding during the period (the denominator). Additionally, the weighted average common shares outstanding for the three- and nine-month periods ended September 30, 2021 include 9,302,718 shares issuable to the former equity holders of IriSys since the acquisition date (see note 10). To calculate diluted income or loss per share, the numerator and denominator are adjusted to eliminate the income or loss and the dilutive effects on shares, respectively, caused by outstanding common stock options, warrants and unvested restricted stock units, using the treasury stock method, if the inclusion of such instruments would be dilutive. For all periods presented, the Company incurred a net loss. In periods of net loss, the inclusion of dilutive securities would be antidilutive because it would reduce the amount of loss incurred per share. As a result, no additional dilutive shares were included in diluted loss per share, and there were no differences between basic and diluted loss per share. The following table presents the potentially dilutive securities that were excluded from the computations of diluted loss per share: Three months ended September 30, Nine months ended September 30, 2021 2020 2021 2020 Restricted stock units 708,965 896,537 377,437 703,679 Stock options 4,965,826 3,613,173 4,496,878 3,480,572 Warrants 348,664 348,664 348,664 348,664 Amounts in the table above reflect the common stock equivalents of the noted instruments. Recently adopted accounting pronouncements On January 1, 2020, the Company adopted ASU 2018-13, “ Fair Value Measurement (Topic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement ” (“ASU 2018-13”). ASU 2018-13 removes, modifies and adds certain disclosure requirements in Topic 820 “ Fair Value Measurement ”. There was no impact upon adoption because the Company is not currently required to provide any of the disclosures impacted by the new standard. On January 1, 2021, the Company adopted ASU No. 2016-13, “ Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments” (“ASU 2016-13”), a new standard for measuring expected credit losses. That guidance impacts the measurement of doubtful accounts receivable, among other things. There was no impact upon adoption because the Company does not currently have any significant exposure to credit losses. In March 2020, the FASB issued ASU 2020-04, "Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting" ("ASU 2020-04"). This ASU provides temporary optional expedients and exceptions to the guidance on contract modifications and hedge accounting to ease the financial reporting burdens of the expected market transition from the London Interbank Offered Rate and other interbank offered rates to alternative reference rates. In January 2021, the FASB issued ASU 2021-01, which refines the scope of Topic 848 and clarifies some of its guidance as part of the FASB’s monitoring of global reference rate activities. The new guidance was effective upon issuance, and the Company is allowed to elect to apply the amendments prospectively through December 31, 2022. The Company is currently evaluating the impact this standard will have on its consolidated financial statements.

Acquisition of IriSys

Acquisition of IriSys	9 Months Ended
	Sep. 30, 2021
Business Combinations [Abstract]
Acquisition of IriSys	(3)  Acquisition of IriSys On August 13, 2021 , the Company acquired all of the units of IriSys, LLC (“IriSys”) pursuant to a unit purchase agreement. IriSys provides contract pharmaceutical product development and manufacturing services, specializing in formulation research and development and good manufacturing practices of clinical trial materials and specialty pharmaceutical products. The acquisition advances the Company’s ongoing growth strategy and leads to key synergies within business development, clinical development and commercial scale-up, as well as a strong cultural alignment and fit between the companies. The aggregate purchase price consideration was comprised of cash consideration, a subordinated promissory note and a contractual obligation to issue 9,302,718 shares of the Company’s common stock on the six-month anniversary of the closing, subject to a working capital adjustment. The following table summarizes the estimated consideration paid: August 13, 2021 Cash paid, net of cash acquired $ 24,006 Fair value of shares issuable to former equity holders of IriSys 20,931 Fair value of note with former equity holder of IriSys 5,240 Total estimated consideration $ 50,177 The fair value of the shares issuable was determined by using the price of the Company's common stock on the acquisition date, less a discount for lack of marketability due to the shares being unregistered shares of the Company. The fair value of the note was determined using a discounted cash flow analysis that incorporated an estimate of the market interest rate for debt of similar terms and credit risk on the acquisition date. The Company incurred $ 1,211 in transaction costs related to the acquisition that were expensed as incurred and classified as selling, general and administrative expenses. The following table summarizes the provisional fair values of the assets acquired and liabilities assumed at the date of acquisition: As of August 13, 2021 Assets acquired: Accounts receivable $ 912 Contract assets 505 Inventory 685 Prepaid expenses and other assets 91 Property and equipment 9,304 Right of use assets 5,559 Intangible assets 6,128 Goodwill 35,249 Other noncurrent liabilities 146 Total assets acquired $ 58,579 Liabilities assumed: Accounts payable $ 730 Accrued expenses and other liabilities 1,512 Operating lease liability 5,559 Debt from finance loan 415 Other liabilities 186 Total liabilities assumed $ 8,402 Net assets acquired $ 50,177 The amounts above represent the Company's current provisional fair value estimates and are subject to subsequent adjustments as additional information is obtained and valuations are finalized during the measurement period. The primary areas of estimates that are not yet finalized include the final outcome of the net working capital adjustment, certain tangible assets acquired and liabilities assumed, as well as the identifiable intangible assets. The purchase price was allocated to the tangible assets and identifiable intangible assets acquired and liabilities assumed based on their acquisition date estimated fair values. The identifiable intangible assets consisting of customer relationships, acquired backlog and trademark and tradename were assigned provisional fair values of $ 4,830 , $ 957 and $ 341 , respectively. Customer relationships, acquired backlog, and trademarks and trade names are subject to amortization on a straight-line basis and are being amortized over 12 , 2.4 and 1.5 years, respectively. The fair value of property, plant and equipment was determined using a cost approach valuation method. The customer relationships and acquired backlog were valued using the multi-period excess earnings method and trademarks and trade names were valued using the relief from royalty method. These methods require several judgments and assumptions to determine the fair value of intangible assets, including revenue growth rates, discount rates, EBITDA margins, and tax rates, among others. These nonrecurring fair value measurements are Level 3 measurements within the fair value hierarchy. Goodwill represents the excess of the purchase price over the net identifiable tangible and intangible assets acquired. The goodwill related to the acquisition was attributable to expected synergies, the value of the assembled workforce as well as the collective experience of the management team with regards to its operations, customers, and industry. The goodwill is deductible for tax purposes. Results for the three and nine months ended September 30, 2021 included revenue of $ 1,490 and net loss of $ 303 from IriSys. The following table presents unaudited supplemental pro forma financial information as if the IriSys acquisition had occurred on January 1, 2020: Three months ended September 30, Nine months ended September 30, 2021 2020 2021 2020 Revenue $ 19,102 $ 21,977 $ 60,742 $ 62,844 Net loss ( 3,821 ) ( 2,399 ) ( 9,625 ) ( 18,589 ) The pro forma financial information presented above has been prepared by combining the Company's historical results and the historical results of IriSys and adjusting those results to eliminate historical transaction costs and to reflect the effects of the acquisition as if they occurred on January 1, 2020. The effects of the acquisition on the historical pro forma financial information include additional depreciation and amortization expense from the increase of asset carrying values to fair value, the adoption of new accounting standards, additional interest expense from the issuance of the subordinated promissory note and the elimination of interest expense related to indebtedness of IriSys prior to the acquisition. These results do not purport to be indicative of the results of operations which actually would have resulted had the acquisitions occurred on the date indicated above, or that may result in the future, and do not reflect potential synergies or additional costs following the acquisition.

Inventory

Inventory	9 Months Ended
	Sep. 30, 2021
Inventory Disclosure [Abstract]
Inventory	(4)   Inventory Inventory is stated at the lower of cost or net realizable value. Included in inventory are raw materials and work-in-process used in the production of commercial products. Items are issued out of inventory using the first-in, first-out method. Inventory was as follows: September 30, 2021 December 31, 2020 Raw materials $ 3,662 $ 3,373 Work in process 2,737 5,061 Finished goods 3,475 3,544 Inventory, prior to provision 9,874 11,978 Provision for inventory obsolescence ( 434 ) ( 366 ) Inventory $ 9,440 $ 11,612 Adjustments to inventory are determined at the raw materials, work-in-process, and finished good levels to reflect obsolescence or impaired balances. Inventory is primarily ordered to meet specific customer orders and largely reflects demand. Factors influencing inventory obsolescence include changes in demand, product life cycle, product pricing, physical deterioration and quality concerns.

Property, Plant and Equipment

Property, Plant and Equipment	9 Months Ended
	Sep. 30, 2021
Property Plant And Equipment [Abstract]
Property, Plant and Equipment	(5)   Property, plant and equipment Property, plant and equipment consists of the following: September 30, 2021 December 31, 2020 Land $ 3,263 $ 3,263 Building and improvements 23,891 20,924 Furniture, office and computer equipment 5,926 5,879 Manufacturing equipment 51,948 39,349 Construction in progress 885 5,568 Property, plant and equipment, gross 85,913 74,983 Less: accumulated depreciation ( 35,892 ) ( 31,142 ) Property, plant and equipment, net $ 50,021 $ 43,841 During the nine months ended September 30, 2021, $ 120 of interest expense was capitalized to construction in process.

Goodwill and Other Intangible A

Goodwill and Other Intangible Assets	9 Months Ended
	Sep. 30, 2021
Goodwill And Intangible Assets Disclosure [Abstract]
Goodwill and Other Intangible Assets	(6)  Goodwill and other i ntangible assets The following table presents the rollforward of goodwill: Nine months ended September 30, 2021 Beginning balance $ 4,319 Acquisition of IriSys 35,249 Ending balance $ 39,568 The following table presents the components of other intangible assets: September 30, 2021 December 31, 2020 Gross value Accumulated amortization Carrying value Gross value Accumulated amortization Carrying value Customer relationships $ 20,330 $ 15,553 $ 4,777 $ 15,500 $ 14,800 $ 700 Backlog 957 52 905 — — — Trademarks and tradenames 341 30 311 — — — Total $ 21,628 $ 15,635 $ 5,993 $ 15,500 $ 14,800 $ 700 The following table presents estimated future amortization of other intangible assets: Twelve months ended September 30, 2022 $ 1,026 2023 882 2024 515 2025 403 2026 403 Thereafter 2,764 Total $ 5,993

Accrued Expenses and Other Curr

Accrued Expenses and Other Current Liabilities	9 Months Ended
	Sep. 30, 2021
Payables And Accruals [Abstract]
Accrued Expenses and Other Current Liabilities	(7)   Accrued expenses and other current liabilities Accrued expenses and other current liabilities consist of the following: September 30, 2021 December 31, 2020 Payroll and related costs $ 3,782 $ 1,481 Current portion of contract liabilities (see note 11) 2,316 1,447 Professional and consulting fees 844 432 Property, plant and equipment 44 551 Other 870 469 Total $ 7,856 $ 4,380

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2021
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	(8)   Commitments and contingencies Litigation The Company is involved, from time to time, in various claims and legal proceedings arising in the ordinary course of its business. Except as disclosed below, the Company is not currently a party to any such claims or proceedings that, if decided adversely to it, would either individually or in the aggregate have a material adverse effect on its business, financial condition or results of operations. On May 31, 2018, a securities class action lawsuit (the “Securities Litigation”) was filed against the Company and certain of its officers and directors (collectively, the "Defendants") in the U.S. District Court for the Eastern District of Pennsylvania (the "Court") (Case No. 2:18-cv-02279-MMB) that purported to state a claim for alleged violations of Section 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended, and Rule 10(b)(5) promulgated thereunder, based on statements made by the Company concerning the New Drug Application (“NDA”) for IV meloxicam. The complaint seeks unspecified damages, interest, attorneys’ fees and other costs. On December 10, 2018, the lead plaintiff filed an amended complaint that asserted the same claims and sought the same relief but included new allegations and named additional officers as defendants. On February 8, 2019, the Company filed a motion to dismiss the amended complaint in its entirety, which the lead plaintiff opposed on April 9, 2019. On May 9, 2019, the Company filed its response and briefing was completed on the motion to dismiss. In response to questions from the Court, the parties submitted supplemental briefs regarding the motion to dismiss the amended complaint during the fall of 2019. On February 18, 2020, the motion to dismiss was granted by the Court without prejudice. On April 25, 2020, the plaintiff filed a second amended complaint. The Company filed a motion to dismiss the second amended complaint on June 18, 2020. The plaintiff filed an opposition to the Company’s motion to dismiss on August 17, 2020. On September 16, 2020, the Company filed a reply in support of its motion to dismiss. On March 1, 2021, the Court denied the Company’s second motion to dismiss. On June 21, 2021, the Defendants filed an answer and affirmative defenses to the second amended complaint. A Preliminary Pretrial Conference before the Court occurred on August 3, 2021. The parties have begun discovery and class certification briefing, which the Court has ordered to be completed by December 30, 2021. All expert and fact discovery must be completed by March 15, 2022. In connection with the separation of the Company's former acute care research and development business into a new standalone entity named Baudax Bio, Inc. ("Baudax Bio"), Baudax Bio accepted assignment by the Company of all of its obligations in connection with the Securities Litigation and agreed to indemnify it for all liabilities related to the Securities Litigation. The Company and Baudax Bio believe that the lawsuit is without merit and intend to vigorously defend against it, unless and until a resolution satisfactory to the Company can be achieved. Purchase commitments As of September 30, 2021 , the Company had outstanding cancelable and non-cancelable purchase commitments in the aggregate amount of $ 4,506 related to inventory, capital expenditures and other goods and services. Employment agreements and certain other contingencies The Company has entered into employment agreements with each of its named executive officers that provide for, among other things, severance commitments of up to $ 1,250 should the Company terminate the named executive officers for convenience or if certain events occur following a change in control. In addition, the Company is subject to other contingencies of up to $ 3,566 in the aggregate if certain events occur following a change in control.

Debt

Debt	9 Months Ended
	Sep. 30, 2021
Debt Disclosure [Abstract]
Debt	(9)   Debt The following table presents the components and classification of debt: September 30, 2021 December 31, 2020 Debt principal: Terms loans under Credit Agreement $ 100,000 $ 116,000 Note with former equity holder of IriSys 6,117 — Other 415 3,316 Debt principal 106,532 119,316 Debt adjustments: Unamortized deferred issuance costs ( 10,017 ) ( 10,359 ) Exit fee accretion 627 614 Unamortized original discount ( 815 ) — Carrying value of debt $ 96,327 $ 109,571 Current portion of debt $ — $ 1,474 Current portion of related party debt 2,039 — Debt, net of current portion 91,029 108,097 Related party debt, net of current portion 3,259 — Carrying value of debt $ 96,327 $ 109,571 The following table presents the future maturity of debt principal: Twelve months ended September 30, 2022 $ 2,039 2023 2,039 2024 102,070 2025 39 2026 45 Thereafter 300 Total debt $ 106,532 Term loans under Credit Agreement The Company is currently party to a credit agreement (the “Credit Agreement”) with Athyrium Opportunities III Acquisition LP (“Athyrium”). The Credit Agreement has been fully drawn in the form of $ 48,000 of term A loans and $ 52,000 of term B loans, all of which mature on December 31, 2023 . The Credit Agreement has been amended six times, twice during 2021:  the fifth amendment in February 2021 resulted in a reduction of $ 16,000 principal, a reduction of 1.5 % in the stated interest rate, and a $ 160 settlement of accrued exit fees in exchange for $ 10,100 of cash and $ 9,271 , or 2,202,420 shares, of common stock issued, as well as certain other changes to the terms of the debt. Of the total common stock issued, $ 6,060 was applied to the principal balance and accrued exit fee, and substantially all of the remainder was added to unamortized deferred financing costs and will be amortized as interest over the remaining term of the debt.  The sixth amendment in August 2021 provided (i) Athyrium’s consent regarding (i) the acquisition of IriSys and certain resulting changes to the Credit Agreement, (ii) for the inclusion of an updated fee letter of $ 500 in connection with the sixth amendment; and (iii) an extension of the maturity date of the term loans from March 31, 2023 to December 31, 2023 . The term loans under the Credit Agreement bear a rate of interest equal to the three-month LIBOR rate, with a 1 % floor plus 8.25 % per annum . The term loans require the Company to pay a 1 % exit fee on all repayments. At September 30, 2021 , the aggregate exit fee payable was $ 1,000 , and the cumulative exit fee accreted was $ 627 . The exit fees are being accreted to the carrying amount of the debt using the effective interest method over the term of the loan. In addition, if the Company makes any prepayments prior to maturity, the Company would be subject to the following prepayment premiums as a percentage of the amount repaid: (i) term A loans at 2.5 % through March 31, 2022 with no penalty thereafter; and (ii) term B loans at 5.0 % through March 31, 2022 and 2.5 % thereafter. The Credit Agreement contains certain usual and customary affirmative and negative covenants, as well as financial covenants that the Company will need to satisfy on a monthly and quarterly basis, including maintaining a permitted net leverage ratio (which is the Company’s indebtedness under the Credit Agreement, net of cash and cash equivalents, divided by EBITDA, each as defined in the Credit Agreement) and liquidity amount. As of September 30, 2021 , the Company was in compliance with its covenants under the Credit Agreement. In connection with the Credit Agreement, the Company issued warrants to each of Athyrium and its affiliate, Athyrium Opportunities II Acquisition LP (“Athyrium II”), to purchase an aggregate of 348,664 shares of the Company’s common stock with an exercise price of $ 1.73 per share. See note 10 for additional information. The warrants are exercisable through November 17, 2024 . In connection with the Credit Agreement and the six subsequent amendments, the Company has paid financing costs, has incurred costs to record and subsequently to adjust the value of the warrants described above and has been accreting the exit fee described above. These costs are being recognized in interest expense using the effective interest method over the term of the Credit Agreement, resulting in non-cash interest expense of $ 1,389 and $ 1,303 in the third quarters of 2021 and 2020, respectively, and $ 4,469 and $ 4,222 in the first nine months of 2021 and 2020, respectively. At September 30, 2021 , the overall effective interest rate, including cash paid for interest and non-cash interest expense, was 13.8 %. Note with former equity holder of IriSys In connection with the acquisition of IriSys (see note 3), the Company issued a subordinated promissory note to a former equity holder of Irisys in the aggregate principal amount of $ 6,117 (the “Note”). The Note is unsecured, has a three-year term, and bears interest at a rate of 6 % per annum. The Note must be repaid in three equal annual installments through its maturity date, August 13, 2024 . The Note may be prepaid in whole or in part at any time prior to the maturity date. The Note is expressly subordinated in right of payment and priority to the term loans under the Credit Agreement with Athyrium. The Note was initially recognized at fair value as part of the consideration paid for the acquisition of IriSys, resulting in an original discount recognized of $ 877 that is being recognized as interest expense using the effective interest method over the term of the Note. At September 30, 2021 , the overall effective interest rate, including the amortization of the original discount, was 13.0 %. The former equity holder of IriSys beneficially owns more than 10% of the Company's common stock and became a related party as a result of the acquisition (see notes 3 and 10). The Company has accrued interest of $ 49 for the three and nine months ended September 30, 2021 that will become payable to the former equity holder of IriSys on the first anniversary of the acquisition. Other In connection with the acquisition of IriSys (see note 3), the Company assumed a loan with a carrying value of $ 415 at September 30, 2021. In May 2020, the Company entered into a $ 4,416 promissory note with PNC Bank under the Small Business Administration (“SBA”) Paycheck Protection Program of the Coronavirus Aid, Relief and Economic Security Act of 2020 (the “PPP Note”). Shortly after entering into the note, the Company prepaid $ 1,100 of principal to comply with guidance from the SBA that limited the amount that could be borrowed at that time. The note had a two-year term and a stated rate of interest of 1.0 % per annum, which accrued and would have become payable beginning September 2021. In October 2020, the Company submitted a forgiveness application for the PPP Note, and in June 2021, the PPP Note and all accrued interest thereon was forgiven. Upon receiving the decision, the Company recorded a gain on extinguishment of debt of $ 3,352 , consisting of forgiveness of $ 3,316 of principal and $ 36 of accrued interest.

Stockholders_ Equity or Deficit

Stockholders’ Equity or Deficit	9 Months Ended
	Sep. 30, 2021
Equity [Abstract]
Stockholders’ Equity or Deficit	(10)   Shareholders’ equity or deficit Capital raises The following table presents the Company’s capital raises since its initial public offering: Date or period Shares of common stock issued Gross proceeds Offering expenses Net proceeds Initial public offering March 12, 2014 4,312,500 $ 34,500 $ ( 4,244 ) $ 30,256 Private placement July 7, 2015 1,379,311 16,000 ( 1,188 ) 14,812 Underwritten public offering August 19, 2016 1,986,666 14,900 ( 1,533 ) 13,367 Underwritten public offering December 16, 2016 6,670,000 40,020 ( 3,132 ) 36,888 2018 common stock purchase agreement with Aspire Capital Year ended December 31, 2018 1,950,000 16,999 — 16,999 2019 common stock purchase agreement with Aspire Capital Fourth quarter 2020 4,690,972 11,172 ( 78 ) 11,094 Underwritten public offering May 12, 2021 15,333,332 34,500 ( 2,397 ) 32,103 Shares issuable to former equity holders of IriSys As part of the consideration paid for the acquisition of IriSys (see note 3), the Company agreed to issue 9,302,718 shares of its common stock on the six month anniversary of the Closing and incurred costs of approximately $ 600 to file a registration statement on Form S-3 in connection with the resale of such shares with the SEC in September 2021. The fair value of the forward contract was estimated to be $ 20,931 based on the closing price of the Company’s common stock on the acquisition date discounted for a lack of marketability. The Company recognized the instrument as shareholders' equity at fair value as of the acquisition date. Aspire common stock purchase agreement The Company is currently party to an amended common stock purchase agreement with Aspire Capital Fund LLC (“Aspire Capital”) originally entered into during 2019, and most recently amended in February 2021 (as amended, the “2019 Common Stock Purchase Agreement”). The 2019 Common Stock Purchase Agreement provides that, upon the terms and subject to the conditions and limitations set forth in the agreement, Aspire Capital is committed to purchase, at the Company’s sole election, up to an aggregate value of $ 41,172 in shares of common stock. As of September 30, 2021 , there is availability to issue up to $ 30,000 or 6,199,299 shares of common stock under the 2019 Common Stock Purchase Agreement. Athyrium stock issuance agreement In February 2021, the Company entered into a stock issuance agreement with Athyrium in connection with an amendment to its Credit Agreement. See note 9 for additional details. Warrants At September 30, 2021 , warrants to purchase 348,664 shares of common stock were outstanding. The warrants are held by Athyrium, equity-classified, exercisable at $ 1.73 per share and expire in November 2024 . See note 9 for additional details.

Revenue Recognition

Revenue Recognition	9 Months Ended
	Sep. 30, 2021
Revenue From Contract With Customer [Abstract]
Revenue Recognition	(11)   Revenue recognition Contract assets represent revenue recognized for performance obligations completed before an unconditional right to payment exists, and therefore invoicing or associated reporting from the customer regarding the computation of the net product sales has not yet occurred. Generally, the contract assets balance is impacted by the recognition of additional contract assets, offset by amounts invoiced to customers or actual net product sale amounts reported by the commercial partner for the period. The following table presents changes in contract assets and liabilities: Contract assets Contract liabilities Balance at December 31, 2020 $ 7,330 $ 2,695 Changes to the beginning balance of contract assets arising from: Reclassification to receivables as a result of rights to consideration becoming unconditional ( 8,774 ) — Changes in estimate 1,508 — Contract assets recognized since beginning of period, net of reclassification to receivables and changes in estimates 6,745 — Changes to contract liabilities: Amounts billed in advance of contract performance — 4,097 Revenue recognized — ( 4,391 ) Acquisition of IriSys 505 930 Balance at September 30, 2021 $ 7,314 $ 3,331 Less: noncurrent portion — ( 1,015 ) Current portion $ 7,314 $ 2,316 The following table disaggregates revenue by timing of revenue recognition: Three months ended September 30, Nine months ended September 30, 2021 2020 2021 2020 Point in time $ 14,361 $ 17,827 $ 45,947 $ 53,247 Over time 3,876 1,460 7,110 3,339 Total $ 18,237 $ 19,287 $ 53,057 $ 56,586 The Company’s payment terms for manufacturing revenue and development services are typically 30 to 45 days. Profit-sharing revenue is recorded to accounts receivable in the quarter that the product is sold by the commercial partner upon reporting from the commercial partner and payment terms are generally 45 days after quarter end.

Stock-Based Compensation

Stock-Based Compensation	9 Months Ended
	Sep. 30, 2021
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock-Based Compensation	(12)   Stock-based compensation In October 2013, the Company established an equity incentive plan that has been subsequently amended and restated to become the 2018 Amended and Restated Equity Incentive Plan (the “A&R Plan”) At September 30, 2021 , a total of 2,431,418 shares were available for future grants under the A&R Plan. On December 1 st of each year, pursuant to the “Evergreen” provision of the A&R Plan, the number of shares available under the A&R Plan may be increased by the board of directors by an amount equal to 5 % of the outstanding common stock on December 1 st of that year. Stock options Stock options are exercisable generally for a period of 10 years from the date of grant and generally vest over four years . The following table presents information about the fair value of stock options granted: Nine months ended September 30, 2021 2020 Weighted average grant date fair value $ 1.78 $ 8.24 Assumptions used to determine fair value: Range of expected option life 5.5 - 6 years 5.5 - 6 year s Expected volatility 79 - 81 % 75 - 81 % Risk-free interest rate 0.7 - 1.2 % 0.3 - 1.4 % Expected dividend yield — — The intrinsic value of options exercised was negligible in the first nine months of 2021 and $ 1,058 in the first nine months of 2020. The following table presents information about stock option balances and activity: Number of shares Weighted average exercise price Aggregate intrinsic value Weighted average remaining contractual life Balance, December 31, 2020 3,907,010 $ 8.03 Granted 1,575,534 2.64 Exercised ( 80 ) 2.31 Forfeited or expired ( 185,172 ) 6.48 Balance, September 30, 2021 5,297,292 6.48 $ 1 6.0 years Exercisable 3,268,854 8.05 — 3.9 years Included in the table above are 903,542 options outstanding as of September 30, 2021 that were granted outside the A&R Plan. The grants were made pursuant to the NASDAQ inducement grant exception in accordance with NASDAQ Listing Rule 5635(c)(4). Restricted stock units Restricted stock units (“RSUs”) vest over six months to four years depending on the purpose of the award. The fair value of RSUs on the date of grant is measured as the closing price of the Company's common stock on that date. The weighted average grant-date fair value of RSUs awarded to employees was $ 3.49 in the first nine months of 2021 and $ 15.11 in the first nine months of 2020. The fair value of RSUs vested was $ 1,868 in the first nine months of 2021 and $ 3,246 in the first nine months of 2020. The following table presents information about recent RSU activity: Number of shares Weighted average grant date fair value Balance, December 31, 2020 1,516,819 $ 5.67 Granted 743,956 3.49 Vested ( 680,194 ) 7.89 Forfeited ( 106,408 ) 9.26 Balance, September 30, 2021 1,474,173 3.29 Included in the table above are 232,822 time-based RSUs outstanding at September 30, 2021 that were granted outside of the A&R Plan. The grants were made pursuant to the NASDAQ inducement grant exception in accordance with NASDAQ Listing Rule 5635(c)(4). Other information The following table presents the classification of stock-based compensation expense: Nine months ended September 30, 2021 2020 Cost of sales $ 3,081 $ 2,293 Selling, general and administrative expenses 3,300 5,793 Total $ 6,381 $ 8,086 As of September 30, 2021 , there was $ 8,232 of unrecognized compensation expense related to unvested options and RSUs that are expected to vest and will be expensed over a weighted average period of 2.5 years.

Fair Value of Financial Instrum

Fair Value of Financial Instruments	9 Months Ended
	Sep. 30, 2021
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	(13)   Fair value of financial instruments The Company follows the provisions of FASB ASC Topic 820, “ Fair Value Measurements and Disclosures ,” for fair value measurement recognition and disclosure purposes for its financial assets and financial liabilities that are remeasured and reported at fair value each reporting period. The Company measures certain financial assets and liabilities at fair value on a recurring basis, including cash equivalents, short-term investments and certain warrants. The Company’s assessment of the significance of a particular input to the fair value measurement requires judgment and may affect the valuation of financial assets and financial liabilities and their placement within the fair value hierarchy. Categorization is based on a three-tier valuation hierarchy, which prioritizes the inputs used in measuring fair value, as follows: • Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities; • Level 2: Inputs that are other than quoted prices in active markets for identical assets and liabilities, inputs that are quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are either directly or indirectly observable; and • Level 3: Unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions. Items measured at fair value on a recurring basis Cash equivalents of $ 15,411 at September 30, 2021 and $ 6,583 at December 31, 2020 consisted entirely of money market mutual funds whose fair value were determined using Level 1 measurements. Fair value disclosures The Company follows the disclosure provisions of FASB ASC Topic 825, “ Financial Instruments ” (ASC 825), for disclosure purposes for financial assets and financial liabilities that are not measured at fair value. As of September 30, 2021, the financial assets and liabilities recorded on the consolidated balance sheets that are not measured at fair value on a recurring basis include accounts receivable, accounts payable and accrued expenses. The carrying values of these accounts approximate fair value due to their short-term nature. The fair value of long-term debt, where a quoted market price is not available, is evaluated based on, among other factors, interest rates currently available to the Company for debt with similar terms, remaining payments and considerations of the Company’s creditworthiness. The Company determined that the recorded book value of its debt, a level 2 measurement, approximated fair value at September 30, 2021 due to the recent issuances and amendment of those instruments and taking into consideration management's current evaluation of market conditions.

Leases

Leases	9 Months Ended
	Sep. 30, 2021
Lessee Disclosure [Abstract]
Leases	(14)   Leases The Company determines if an arrangement is a lease at inception. The arrangement is a lease if it conveys the right to the Company to control the use of identified property, plant, or equipment for a period of time in exchange for consideration. Options to extend the lease are included in the lease term if the options are reasonably certain to be exercised. Operating lease expense is recognized on a straight-line basis over the lease term. Operating lease balances are presented as separate captions on the balance sheets. Finance lease assets are included in property, plant and equipment. Finance lease liabilities are included in debt. The Company is party to two operating leases for development facilities in California and Georgia that end in 2031 and 2025 , respectively, as well as other immaterial operating leases for office space, storage and office equipment. The development facility leases each include options to extend, none of which are included in the lease terms. Short-term and variable lease costs were not material for the periods presented. The development facility leases do not provide an implicit rate, so the Company uses its incremental borrowing rate to discount the lease liabilities. Undiscounted future lease payments for the two development leases, which were the only material noncancelable leases at September 30, 2021, were as follows: Twelve months ended September 30, 2022 $ 1,130 2023 1,158 2024 1,186 2025 1,189 2026 1,089 Thereafter 5,086 Total lease payments 10,838 Less imputed interest ( 4,842 ) Total operating lease liabilities $ 5,996 At September 30, 2021 , the weighted average remaining lease term was 8.9 years, and the weighted average discount rate was 14.2 %. For the third quarter, total lease cost was $ 161 in 2021 and $ 76 in 2020. For the nine months ended September 30, total lease cost was $ 347 in 2021 and $ 234 in 2020.

Summary of Significant Accoun_2

Summary of Significant Accounting Principles (Policies)	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Basis of Presentation and Principles of Consolidation	Basis of presentation and principles of consolidation The accompanying unaudited consolidated financial statements of the Company and its subsidiaries have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information. In accordance with Securities and Exchange Commission ("SEC") rules for interim financial statements, certain information required by U.S. GAAP may be condensed or omitted. The Company’s consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated. In the opinion of management, the accompanying consolidated financial statements include all normal and recurring adjustments (which consist primarily of accruals, estimates and assumptions that impact the financial statements) considered necessary to present fairly the Company’s results for the interim periods. Operating results for interim periods are not necessarily indicative of the results that may be expected for the full year. The accompanying unaudited interim consolidated financial statements should be read in conjunction with the annual audited financial statements and related notes included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020.
Use of Estimates	Use of estimates The preparation of financial statements and the notes to the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from such estimates.
Business combinations	Business combinations The Company measures the purchase price paid for acquired companies based on fair value and allocates that purchase price to the assets acquired and liabilities assumed based on their estimated fair values. Valuations are performed to assist in determining the fair values of assets acquired and liabilities assumed, which requires management to make estimates and assumptions, in particular with respect to intangible assets. Management makes estimates of fair value based upon assumptions believed to be reasonable. These estimates are based in part on historical experience and information obtained from the acquired companies and expectations of future cash flows. Costs associated with the transaction are expensed as incurred as selling, general and administrative expenses.
Cash and Cash Equivalents	Cash and cash equivalents Cash and cash equivalents represent cash in banks and highly liquid short-term investments that have maturities of three months or less when acquired. These highly liquid short-term investments are both readily convertible to known amounts of cash and so near to their maturity that they present insignificant risk of changes in value due to changes in interest rates.
Property, plant and Equipment	Property, plant and equipment Property, plant and equipment are recorded at cost less accumulated depreciation and amortization. Depreciation and amortization are computed using the straight-line method over the estimated useful lives of the assets, which are as follows: three to ten years for furniture, office and computer equipment; six to ten years for manufacturing equipment; 40 years for buildings; and the shorter of the lease term or useful life for leasehold improvements. Repairs and maintenance costs are expensed as incurred. The Company reviews the carrying value of property, plant and equipment for recoverability whenever events occur or changes in circumstances indicate that the carrying amount of individual assets or asset groups may not be recoverable.
Goodwill and Intangible Assets	Goodwill and intangible assets Goodwill represents the excess of purchase price over the fair value of net assets acquired by the Company. Goodwill is not amortized but assessed for impairment on an annual basis or more frequently if impairment indicators exist. The impairment analysis for goodwill consists of an optional qualitative assessment potentially followed by a quantitative analysis. If the Company determines that the carrying value of its reporting unit exceeds its fair value, an impairment charge is recorded for the excess. The Company performs its annual goodwill impairment test as of November 30 th , or whenever an event or change in circumstance occurs that would require reassessment of the recoverability of goodwill. In performing the evaluation, the Company assesses qualitative factors such as overall financial performance, anticipated changes in industry and market conditions, and competitive environments. Definite-lived intangible assets are amortized on a straight-line basis over their estimated useful life. The Company is required to review the carrying value of definite-lived intangible assets for recoverability whenever events occur or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable.
Revenue Recognition	Revenue recognition The Company generates revenues from manufacturing, packaging, research and development and related services for multiple pharmaceutical companies. Manufacturing Manufacturing and other related services revenue is recognized upon transfer of control of a product to a customer, generally upon shipment, based on a transaction price that reflects the consideration the Company expects to be entitled to as specified in the agreement with the commercial partner, which could include pricing and volume-based adjustments. Profit-sharing In addition to manufacturing and packaging revenue, certain customer agreements may have intellectual property sales-based profit-sharing and/or royalties consideration, collectively referred to as profit-sharing, computed on the net product sales of the commercial partner. Profit-sharing revenues are generally recognized under the terms of the applicable license, development and/or supply agreement. For arrangements that include sales-based profit-sharing where the license for intellectual property is deemed to be the predominant item to which the profit-sharing relates, the Company recognizes revenue when the related sales occur by the commercial partner. For arrangements that include sales-based profit-sharing where the license for intellectual property is not deemed to be the predominant item to which the profit-sharing relates, the Company recognizes revenue upon transfer of control of the manufactured product. In these cases, significant judgment is required to calculate the estimated variable consideration from such profit-sharing using the expected value method based on historical commercial partner pricing and deductions. Estimated variable consideration is partially constrained due to the uncertainty of price adjustments made by the Company’s commercial partners, which are outside of the Company’s control. Factors causing price adjustments by the Company’s commercial partners include increased competition in the products’ markets, mix of volume between the commercial partners’ customers, and changes in government pricing. Research and development Research and development revenue includes services associated with formulation, process development, clinical trials materials services, as well as custom development of manufacturing processes and analytical methods for a customer’s non-clinical, clinical and commercial products. Such revenues are recognized at a point in time or over time depending on the nature and particular facts and circumstances associated with the contract terms. In contracts that specify milestones, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. Milestone payments related to arrangements under which the Company has continuing performance obligations are deferred and recognized over the period of performance. Milestone payments that are not within the Company’s control, such as submission for approval to regulators by a commercial partner or approvals from regulators, are not considered probable of being achieved until those submissions are submitted by the customer or approvals are received. In contracts that require revenue recognition over time, the Company utilizes input or output methods, depending on the specifics of the contract, that compare the cumulative work-in-process to date to the most current estimates for the entire performance obligation. Under these contracts, the customer typically owns the product details and process, which have no alternative use. These projects are customized to each customer to meet its specifications and typically only one performance obligation is included. Each project represents a distinct service that is sold separately and has stand-alone value to the customer. The customer also retains control of its product as the product is being created or enhanced by the Company’s services and can make changes to its process or specifications upon request.
Concentration of Credit Risk	Concentration of credit risk Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash, cash equivalents and accounts receivable. The Company manages its cash and cash equivalents based on established guidelines relative to diversification and maturities to maintain safety and liquidity. The Company’s accounts receivable balances are primarily concentrated among three customers. If any of these customers’ receivable balances should be deemed uncollectible, it could have a material adverse effect on the Company’s results of operations and financial condition. The Company is dependent on its relationships with a small number of commercial partners. The Company's three largest customers generated 81 % and 88 % of its revenues for the three and nine months ended September 30, 2021, respectively.
Stock-based Compensation Expense	Stock-based compensation expense The Company measures employee stock-based awards at grant-date fair value and recognizes employee compensation expense on a straight-line basis over the vesting period of the award. The Company accounts for forfeitures as they occur. Determining the appropriate fair value of stock options requires the input of subjective assumptions, including the expected life of the option and expected stock price volatility. The Company uses the Black-Scholes option pricing model to value its stock option awards. The assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. As a result, if factors change and/or management uses different assumptions, stock-based compensation expense could be materially different for future awards. The expected life of stock options was estimated using the “simplified method,” which is based on the average of the vesting tranches and the contractual life of each grant. For stock price volatility, the Company uses the historical volatility of its publicly traded stock in order to estimate future stock price trends. The risk-free interest rate is based on U.S. Treasury notes with a term approximating the expected life of the option. Upon exercise of stock options or vesting of restricted stock units, the holder may elect to cover tax withholdings by forfeiting shares of an equivalent value. In such cases, the Company issues net new shares to the holder, pays the tax withholding on behalf of the participant and presents the payment similar to a capital distribution: a reduction to additional paid-in-capital and a financing cash outflow in the consolidated financial statements. For non-employee stock-based awards, the Company recognizes compensation expense on a straight-line basis over the vesting period of each separated vesting tranche of the award, which is known as the accelerated attribution method. The estimation of the number of stock awards that will ultimately vest requires judgment, and to the extent actual results or updated estimates differ from the Company’s current estimates, such amounts are recognized as an adjustment in the period in which estimates are revised.
Income Taxes	Income taxes Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis, operating losses and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. A valuation allowance is recorded to the extent it is more likely than not that some portion or all of the deferred tax assets will not be realized. A full valuation allowance was recorded as of September 30, 2021 and December 31, 2020. Unrecognized income tax benefits represent income tax positions taken on income tax returns that have not been recognized in the consolidated financial statements. The Company recognizes the benefit of an income tax position only if it is more likely than not (greater than 50%) that the tax position will be sustained upon tax examination, based solely on the technical merits of the tax position. Otherwise, no benefit is recognized. The tax benefits recognized are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. The Company does not anticipate significant changes in the amount of unrecognized income tax benefits over the next year.
Income or Loss Per Share	Income or loss per share Basic income or loss per share is determined by dividing net income or loss (the numerator) by the weighted average common shares outstanding during the period (the denominator). Additionally, the weighted average common shares outstanding for the three- and nine-month periods ended September 30, 2021 include 9,302,718 shares issuable to the former equity holders of IriSys since the acquisition date (see note 10). To calculate diluted income or loss per share, the numerator and denominator are adjusted to eliminate the income or loss and the dilutive effects on shares, respectively, caused by outstanding common stock options, warrants and unvested restricted stock units, using the treasury stock method, if the inclusion of such instruments would be dilutive. For all periods presented, the Company incurred a net loss. In periods of net loss, the inclusion of dilutive securities would be antidilutive because it would reduce the amount of loss incurred per share. As a result, no additional dilutive shares were included in diluted loss per share, and there were no differences between basic and diluted loss per share. The following table presents the potentially dilutive securities that were excluded from the computations of diluted loss per share: Three months ended September 30, Nine months ended September 30, 2021 2020 2021 2020 Restricted stock units 708,965 896,537 377,437 703,679 Stock options 4,965,826 3,613,173 4,496,878 3,480,572 Warrants 348,664 348,664 348,664 348,664 Amounts in the table above reflect the common stock equivalents of the noted instruments.
Recently Adopted Accounting Pronouncements	Recently adopted accounting pronouncements On January 1, 2020, the Company adopted ASU 2018-13, “ Fair Value Measurement (Topic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement ” (“ASU 2018-13”). ASU 2018-13 removes, modifies and adds certain disclosure requirements in Topic 820 “ Fair Value Measurement ”. There was no impact upon adoption because the Company is not currently required to provide any of the disclosures impacted by the new standard. On January 1, 2021, the Company adopted ASU No. 2016-13, “ Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments” (“ASU 2016-13”), a new standard for measuring expected credit losses. That guidance impacts the measurement of doubtful accounts receivable, among other things. There was no impact upon adoption because the Company does not currently have any significant exposure to credit losses. In March 2020, the FASB issued ASU 2020-04, "Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting" ("ASU 2020-04"). This ASU provides temporary optional expedients and exceptions to the guidance on contract modifications and hedge accounting to ease the financial reporting burdens of the expected market transition from the London Interbank Offered Rate and other interbank offered rates to alternative reference rates. In January 2021, the FASB issued ASU 2021-01, which refines the scope of Topic 848 and clarifies some of its guidance as part of the FASB’s monitoring of global reference rate activities. The new guidance was effective upon issuance, and the Company is allowed to elect to apply the amendments prospectively through December 31, 2022. The Company is currently evaluating the impact this standard will have on its consolidated financial statements.
Fair Value Measurement	The Company follows the provisions of FASB ASC Topic 820, “ Fair Value Measurements and Disclosures ,” for fair value measurement recognition and disclosure purposes for its financial assets and financial liabilities that are remeasured and reported at fair value each reporting period. The Company measures certain financial assets and liabilities at fair value on a recurring basis, including cash equivalents, short-term investments and certain warrants. The Company’s assessment of the significance of a particular input to the fair value measurement requires judgment and may affect the valuation of financial assets and financial liabilities and their placement within the fair value hierarchy. Categorization is based on a three-tier valuation hierarchy, which prioritizes the inputs used in measuring fair value, as follows: • Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities; • Level 2: Inputs that are other than quoted prices in active markets for identical assets and liabilities, inputs that are quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are either directly or indirectly observable; and • Level 3: Unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.
Inventory	Inventory is stated at the lower of cost or net realizable value. Included in inventory are raw materials and work-in-process used in the production of commercial products. Items are issued out of inventory using the first-in, first-out method. Adjustments to inventory are determined at the raw materials, work-in-process, and finished good levels to reflect obsolescence or impaired balances. Inventory is primarily ordered to meet specific customer orders and largely reflects demand. Factors influencing inventory obsolescence include changes in demand, product life cycle, product pricing, physical deterioration and quality concerns.
Leases	The Company determines if an arrangement is a lease at inception. The arrangement is a lease if it conveys the right to the Company to control the use of identified property, plant, or equipment for a period of time in exchange for consideration. Options to extend the lease are included in the lease term if the options are reasonably certain to be exercised. Operating lease expense is recognized on a straight-line basis over the lease term.

Summary of Significant Accoun_3

Summary of Significant Accounting Principles (Tables)	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Schedule of Anti-Dilutive Securities	The following table presents the potentially dilutive securities that were excluded from the computations of diluted loss per share: Three months ended September 30, Nine months ended September 30, 2021 2020 2021 2020 Restricted stock units 708,965 896,537 377,437 703,679 Stock options 4,965,826 3,613,173 4,496,878 3,480,572 Warrants 348,664 348,664 348,664 348,664

Acquisition of IriSys (Tables)

Acquisition of IriSys (Tables)	9 Months Ended
	Sep. 30, 2021
Business Combinations [Abstract]
Schedule of Business Acquisition of Purchase Price Consideration	The following table summarizes the estimated consideration paid: August 13, 2021 Cash paid, net of cash acquired $ 24,006 Fair value of shares issuable to former equity holders of IriSys 20,931 Fair value of note with former equity holder of IriSys 5,240 Total estimated consideration $ 50,177
Schedule of Provisional Fair Values of the Assets Acquired and Liabilities Assumed	The following table summarizes the provisional fair values of the assets acquired and liabilities assumed at the date of acquisition: As of August 13, 2021 Assets acquired: Accounts receivable $ 912 Contract assets 505 Inventory 685 Prepaid expenses and other assets 91 Property and equipment 9,304 Right of use assets 5,559 Intangible assets 6,128 Goodwill 35,249 Other noncurrent liabilities 146 Total assets acquired $ 58,579 Liabilities assumed: Accounts payable $ 730 Accrued expenses and other liabilities 1,512 Operating lease liability 5,559 Debt from finance loan 415 Other liabilities 186 Total liabilities assumed $ 8,402 Net assets acquired $ 50,177
Schedule of Supplemental Pro Forma Financial Information	The following table presents unaudited supplemental pro forma financial information as if the IriSys acquisition had occurred on January 1, 2020: Three months ended September 30, Nine months ended September 30, 2021 2020 2021 2020 Revenue $ 19,102 $ 21,977 $ 60,742 $ 62,844 Net loss ( 3,821 ) ( 2,399 ) ( 9,625 ) ( 18,589 )

Inventory (Tables)

Inventory (Tables)	9 Months Ended
	Sep. 30, 2021
Inventory Disclosure [Abstract]
Components of Inventory	Inventory was as follows: September 30, 2021 December 31, 2020 Raw materials $ 3,662 $ 3,373 Work in process 2,737 5,061 Finished goods 3,475 3,544 Inventory, prior to provision 9,874 11,978 Provision for inventory obsolescence ( 434 ) ( 366 ) Inventory $ 9,440 $ 11,612

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	9 Months Ended
	Sep. 30, 2021
Property Plant And Equipment [Abstract]
Schedule of Property, Plant and Equipment	Property, plant and equipment consists of the following: September 30, 2021 December 31, 2020 Land $ 3,263 $ 3,263 Building and improvements 23,891 20,924 Furniture, office and computer equipment 5,926 5,879 Manufacturing equipment 51,948 39,349 Construction in progress 885 5,568 Property, plant and equipment, gross 85,913 74,983 Less: accumulated depreciation ( 35,892 ) ( 31,142 ) Property, plant and equipment, net $ 50,021 $ 43,841

Goodwill and Other Intangible_2

Goodwill and Other Intangible Assets (Tables)	9 Months Ended
	Sep. 30, 2021
Goodwill And Intangible Assets Disclosure [Abstract]
Schedule of Rollforward Goodwill	The following table presents the rollforward of goodwill: Nine months ended September 30, 2021 Beginning balance $ 4,319 Acquisition of IriSys 35,249 Ending balance $ 39,568
Summary of Components of Other Intangible Assets	The following table presents the components of other intangible assets: September 30, 2021 December 31, 2020 Gross value Accumulated amortization Carrying value Gross value Accumulated amortization Carrying value Customer relationships $ 20,330 $ 15,553 $ 4,777 $ 15,500 $ 14,800 $ 700 Backlog 957 52 905 — — — Trademarks and tradenames 341 30 311 — — — Total $ 21,628 $ 15,635 $ 5,993 $ 15,500 $ 14,800 $ 700
Schedule of Finite-Lived Intangible Assets, Estimated Future Amortization Expense	The following table presents estimated future amortization of other intangible assets: Twelve months ended September 30, 2022 $ 1,026 2023 882 2024 515 2025 403 2026 403 Thereafter 2,764 Total $ 5,993

Accrued Expenses and Other Cu_2

Accrued Expenses and Other Current Liabilities (Tables)	9 Months Ended
	Sep. 30, 2021
Payables And Accruals [Abstract]
Summary of Accrued Expenses and Other Current Liabilities	Accrued expenses and other current liabilities consist of the following: September 30, 2021 December 31, 2020 Payroll and related costs $ 3,782 $ 1,481 Current portion of contract liabilities (see note 11) 2,316 1,447 Professional and consulting fees 844 432 Property, plant and equipment 44 551 Other 870 469 Total $ 7,856 $ 4,380

Debt (Tables)

Debt (Tables)	9 Months Ended
	Sep. 30, 2021
Debt Disclosure [Abstract]
Components and Classification of Debt	The following table presents the components and classification of debt: September 30, 2021 December 31, 2020 Debt principal: Terms loans under Credit Agreement $ 100,000 $ 116,000 Note with former equity holder of IriSys 6,117 — Other 415 3,316 Debt principal 106,532 119,316 Debt adjustments: Unamortized deferred issuance costs ( 10,017 ) ( 10,359 ) Exit fee accretion 627 614 Unamortized original discount ( 815 ) — Carrying value of debt $ 96,327 $ 109,571 Current portion of debt $ — $ 1,474 Current portion of related party debt 2,039 — Debt, net of current portion 91,029 108,097 Related party debt, net of current portion 3,259 — Carrying value of debt $ 96,327 $ 109,571
Schedule of Maturities of Debt	The following table presents the future maturity of debt principal: Twelve months ended September 30, 2022 $ 2,039 2023 2,039 2024 102,070 2025 39 2026 45 Thereafter 300 Total debt $ 106,532

Stockholders_ Equity or Defic_2

Stockholders’ Equity or Deficit (Tables)	9 Months Ended
	Sep. 30, 2021
Equity [Abstract]
Summary of Capital Raises Since its Initial Public Offreing	The following table presents the Company’s capital raises since its initial public offering: Date or period Shares of common stock issued Gross proceeds Offering expenses Net proceeds Initial public offering March 12, 2014 4,312,500 $ 34,500 $ ( 4,244 ) $ 30,256 Private placement July 7, 2015 1,379,311 16,000 ( 1,188 ) 14,812 Underwritten public offering August 19, 2016 1,986,666 14,900 ( 1,533 ) 13,367 Underwritten public offering December 16, 2016 6,670,000 40,020 ( 3,132 ) 36,888 2018 common stock purchase agreement with Aspire Capital Year ended December 31, 2018 1,950,000 16,999 — 16,999 2019 common stock purchase agreement with Aspire Capital Fourth quarter 2020 4,690,972 11,172 ( 78 ) 11,094 Underwritten public offering May 12, 2021 15,333,332 34,500 ( 2,397 ) 32,103

Revenue Recognition (Tables)

Revenue Recognition (Tables)	9 Months Ended
	Sep. 30, 2021
Revenue From Contract With Customer [Abstract]
Schedule of Changes in Contract Assets and Liabilities	The following table presents changes in contract assets and liabilities: Contract assets Contract liabilities Balance at December 31, 2020 $ 7,330 $ 2,695 Changes to the beginning balance of contract assets arising from: Reclassification to receivables as a result of rights to consideration becoming unconditional ( 8,774 ) — Changes in estimate 1,508 — Contract assets recognized since beginning of period, net of reclassification to receivables and changes in estimates 6,745 — Changes to contract liabilities: Amounts billed in advance of contract performance — 4,097 Revenue recognized — ( 4,391 ) Acquisition of IriSys 505 930 Balance at September 30, 2021 $ 7,314 $ 3,331 Less: noncurrent portion — ( 1,015 ) Current portion $ 7,314 $ 2,316
Disaggregation of Revenue by Timing of Revenue Recognition	The following table disaggregates revenue by timing of revenue recognition: Three months ended September 30, Nine months ended September 30, 2021 2020 2021 2020 Point in time $ 14,361 $ 17,827 $ 45,947 $ 53,247 Over time 3,876 1,460 7,110 3,339 Total $ 18,237 $ 19,287 $ 53,057 $ 56,586

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2021
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Fair Value of Stock Options Granted	The following table presents information about the fair value of stock options granted: Nine months ended September 30, 2021 2020 Weighted average grant date fair value $ 1.78 $ 8.24 Assumptions used to determine fair value: Range of expected option life 5.5 - 6 years 5.5 - 6 year s Expected volatility 79 - 81 % 75 - 81 % Risk-free interest rate 0.7 - 1.2 % 0.3 - 1.4 % Expected dividend yield — —
Summary of Stock Option Activity	The following table presents information about stock option balances and activity: Number of shares Weighted average exercise price Aggregate intrinsic value Weighted average remaining contractual life Balance, December 31, 2020 3,907,010 $ 8.03 Granted 1,575,534 2.64 Exercised ( 80 ) 2.31 Forfeited or expired ( 185,172 ) 6.48 Balance, September 30, 2021 5,297,292 6.48 $ 1 6.0 years Exercisable 3,268,854 8.05 — 3.9 years
Summary of Restricted Stock Units Activity	The following table presents information about recent RSU activity: Number of shares Weighted average grant date fair value Balance, December 31, 2020 1,516,819 $ 5.67 Granted 743,956 3.49 Vested ( 680,194 ) 7.89 Forfeited ( 106,408 ) 9.26 Balance, September 30, 2021 1,474,173 3.29
Summary of Stock Based Compensation Expense	The following table presents the classification of stock-based compensation expense: Nine months ended September 30, 2021 2020 Cost of sales $ 3,081 $ 2,293 Selling, general and administrative expenses 3,300 5,793 Total $ 6,381 $ 8,086

Leases (Tables)

Leases (Tables)	9 Months Ended
	Sep. 30, 2021
Lessee Disclosure [Abstract]
Schedule of Undiscounted Future Lease Payments for the Development Lease	Undiscounted future lease payments for the two development leases, which were the only material noncancelable leases at September 30, 2021, were as follows: Twelve months ended September 30, 2022 $ 1,130 2023 1,158 2024 1,186 2025 1,189 2026 1,089 Thereafter 5,086 Total lease payments 10,838 Less imputed interest ( 4,842 ) Total operating lease liabilities $ 5,996

Background - Additional Informa

Background - Additional Information (Detail) $ in Thousands	9 Months Ended
	Sep. 30, 2021USD ($)Segment	Dec. 31, 2020USD ($)
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Entity incorporation date	Nov. 15, 2007
Accumulated deficit | $	$ (243,397)	$ (234,384)
Number of operating segment | Segment	1

Summary of Significant Accoun_4

Summary of Significant Accounting Principles - Additional Information (Detail)	Aug. 13, 2021shares	Feb. 13, 2021shares	Sep. 30, 2021	Sep. 30, 2021Customer
Accounts Receivable [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Number of customers				3
Sales Revenue, Net [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Number of customers				3
Sales Revenue, Net [Member] | Customer Concentration Risk [Member] | Cash and Cash Equivalents [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Concentration risk percentage			81.00%	88.00%
Furniture and Office Equipment [Member] | Minimum [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Property, plant and equipment estimated useful lives				3 years
Furniture and Office Equipment [Member] | Maximum [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Property, plant and equipment estimated useful lives				10 years
Manufacturing Equipment [Member] | Minimum [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Property, plant and equipment estimated useful lives				6 years
Manufacturing Equipment [Member] | Maximum [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Property, plant and equipment estimated useful lives				10 years
Buildings [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Property, plant and equipment estimated useful lives				40 years
Leasehold Improvements [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Property, plant and equipment useful life				the shorter of the lease term or useful life
Irisys LLC [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Number of share issued for acquisition | shares	9,302,718	9,302,718

Summary of Significant Accoun_5

Summary of Significant Accounting Principles - Schedule of Anti-Dilutive Securities (Detail) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Restricted Stock Units [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of diluted weighted average shares outstanding	708,965	896,537	377,437	703,679
Stock options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of diluted weighted average shares outstanding	4,965,826	3,613,173	4,496,878	3,480,572
Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of diluted weighted average shares outstanding	348,664	348,664	348,664	348,664

Acquisition of IriSys (Addition

Acquisition of IriSys (Additional Information) (Details) - USD ($) $ in Thousands	Aug. 13, 2021	Feb. 13, 2021	Sep. 30, 2021	Sep. 30, 2021	Sep. 30, 2020
Business Acquisition [Line Items]
Net loss				$ (9,013)	$ (15,831)
Irisys LLC [Member]
Business Acquisition [Line Items]
Date of acquisition agreement	Aug. 13, 2021
Number of share issued for acquisition	9,302,718	9,302,718
Business acquisition transaction costs	$ 1,211	$ 600
Revenues			$ 1,490	1,490
Net loss			$ (303)	$ (303)
Irisys LLC [Member] | Backlog [Member]
Business Acquisition [Line Items]
Indefinite-lived intangible assets fair value	$ 4,830
Intangible asset amortized remaining term	12 years
Irisys LLC [Member] | Trademarks [Member]
Business Acquisition [Line Items]
Indefinite-lived intangible assets fair value	$ 957
Intangible asset amortized remaining term	2 years 4 months 24 days
Irisys LLC [Member] | Trade Names [Member]
Business Acquisition [Line Items]
Indefinite-lived intangible assets fair value	$ 341
Intangible asset amortized remaining term	1 year 6 months

Acquisition of IriSys - Schedul

Acquisition of IriSys - Schedule of Business Acquisition of Purchase Price Consideration (Details) - USD ($) $ in Thousands	Aug. 13, 2021	Sep. 30, 2021
Business Acquisition [Line Items]
Cash paid, net of cash acquired		$ 24,006
Irisys LLC [Member]
Business Acquisition [Line Items]
Cash paid, net of cash acquired	$ 24,006
Fair value of forward equity issuance	20,931
Fair value of note with former members of IriSys	5,240
Estimated future net working capital adjustment	$ (50,177)

Acquisition of IriSys - Sched_2

Acquisition of IriSys - Schedule of Provisional Fair Values of the Assets Acquired and Liabilities Assumed (Details) - Irisys LLC [Member] $ in Thousands	Aug. 13, 2021USD ($)
Assets acquired:
Accounts receivable	$ 912
Contract assets	505
Inventory	685
Prepaid expenses and other assets	91
Property and equipment	9,304
Right of use assets	5,559
Intangible assets	6,128
Goodwill	35,249
Other noncurrent liabilities	146
Total assets acquired	58,579
Liabilities assumed:
Accounts payable	730
Accrued expenses and other liabilities	1,512
Operating lease liability	5,559
Debt from finance loan	415
Other liabilities	186
Total liabilities assumed	8,402
Net assets acquired	$ 50,177

Acquisition of IriSys - Sched_3

Acquisition of IriSys - Schedule of Supplemental Pro Forma Financial Information (Details) - Irisys LLC [Member] - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Business Acquisition [Line Items]
Revenue	$ 19,102	$ 21,977	$ 60,742	$ 62,844
Net loss	$ (3,821)	$ (2,399)	$ (9,625)	$ (18,589)

Inventory - Components of Inven

Inventory - Components of Inventory (Detail) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Inventory Disclosure [Abstract]
Raw materials	$ 3,662	$ 3,373
Work in process	2,737	5,061
Finished goods	3,475	3,544
Inventory, prior to provision	9,874	11,978
Provision for inventory obsolescence	(434)	(366)
Inventory	$ 9,440	$ 11,612

Property, Plant and Equipment -

Property, Plant and Equipment - Schedule of Property, Plant and Equipment (Detail) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Property, Plant and Equipment [Line Items]
Property, plant and equipment	$ 85,913	$ 74,983
Less: accumulated depreciation	(35,892)	(31,142)
Property, plant and equipment, net	50,021	43,841
Land [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment	3,263	3,263
Buildings and Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment	23,891	20,924
Furniture, Office & Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment	5,926	5,879
Manufacturing Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment	51,948	39,349
Construction in Progress [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment	$ 885	$ 5,568

Property, Plant and Equipment_2

Property, Plant and Equipment - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Property, Plant and Equipment [Line Items]
Interest Expense	$ 3,822	$ 4,609	$ 11,680	$ 14,727
Construction in Progress [Member]
Property, Plant and Equipment [Line Items]
Interest Expense			$ 120

Goodwill and Other Intangible_3

Goodwill and Other Intangible Assets - Schedule of Rollforward Goodwill (Detail) $ in Thousands	9 Months Ended
	Sep. 30, 2021USD ($)
Goodwill And Intangible Assets Disclosure [Abstract]
Goodwill, Beginning Balance	$ 4,319
Acquisition of IriSys	35,249
Goodwill, Ending Balance	$ 39,568

Goodwill and Other Intangible_4

Goodwill and Other Intangible Assets - Summary of Components of Other Intangible Assets (Detail) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Finite-Lived Intangible Assets [Line Items]
Gross value	$ 21,628	$ 15,500
Accumulated amortization	15,635	14,800
Carrying value	5,993	700
Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Gross value	20,330	15,500
Accumulated amortization	15,553	14,800
Carrying value	4,777	700
Backlog [Member]
Finite-Lived Intangible Assets [Line Items]
Gross value	957	0
Accumulated amortization	52	0
Carrying value	905	0
Trademarks and Tradenames [Member]
Finite-Lived Intangible Assets [Line Items]
Gross value	341	0
Accumulated amortization	30	0
Carrying value	$ 311	$ 0

Goodwill and Other Intangible_5

Goodwill and Other Intangible Assets - Schedule of Finite-Lived Intangible Assets, Estimated Future Amortization Expense (Detail) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Goodwill And Intangible Assets Disclosure [Abstract]
2022	$ 882
2023	515
2024	403
2025	403
2026	2,764
Thereafter	5,993
Net Intangible Assets, Definite-lived	$ 5,993	$ 700

Accrued Expenses and Other Cu_3

Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Detail) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Payables And Accruals [Abstract]
Payroll and related costs	$ 3,782	$ 1,481
Current portion of contract liabilities (see note 11)	2,316	1,447
Professional and consulting fees	844	432
Property, plant and equipment	44	551
Other	870	469
Total	$ 7,856	$ 4,380

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail) $ in Thousands	Sep. 30, 2021USD ($)
Executive Officer [Member]
Supply Commitment [Line Items]
Potential severance commitments arrangement consideration	$ 1,250
Other Contingencies	3,566
Purchase Commitment [Member]
Supply Commitment [Line Items]
Purchase commitment non cancelable and cancelable	$ 4,506

Debt - Components and Classific

Debt - Components and Classification of Debt (Detail) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Debt Instrument [Line Items]
Debt principal	$ 106,532	$ 119,316
Unamortized deferred issuance costs	(10,017)	(10,359)
Exit fee accretion	627	614
Unamortized original discount	(815)
Carrying value of debt	96,327	109,571
Current portion of debt		1,474
Current portion of related party debt	2,039
Debt, net	91,029	108,097
Related party debt, net of current portion	3,259
Term Loans Under Credit Agreement [Member]
Debt Instrument [Line Items]
Debt principal	100,000	116,000
Exit fee accretion	627
Note with Former [Member]
Debt Instrument [Line Items]
Debt principal	6,117
Other [Member]
Debt Instrument [Line Items]
Debt principal	$ 415	$ 3,316

Debt - Schedule of Maturities o

Debt - Schedule of Maturities of Debt (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Debt Disclosure [Abstract]
2022	$ 2,039
2023	102,070
2024	39
2025	45
2026	300
Thereafter	106,532
Total debt	$ 106,532	$ 119,316

Debt - Additional Information (

Debt - Additional Information (Detail) $ / shares in Units, $ in Thousands	1 Months Ended		3 Months Ended		9 Months Ended
	Feb. 28, 2021USD ($)	May 31, 2020USD ($)	Sep. 30, 2021USD ($)$ / shares	Sep. 30, 2020USD ($)	Sep. 30, 2021USD ($)$ / sharesshares	Sep. 30, 2020USD ($)	Dec. 31, 2020USD ($)	Nov. 17, 2017
Debt Instrument [Line Items]
Principal balance and exit fee due			$ 2,039		$ 2,039
Carrying value of debt			96,327		96,327		$ 109,571
Debt principal			106,532		106,532		119,316
Debt instrument, exit fee			627		627		614
Non-cash interest expense					4,531	$ 4,222
Gain on extinguishment of debt					3,352
Unamortized original discount			$ 815		$ 815
Athyrium Opportunities II Acquisition LP [Member] | Seven Year Warrant [Member]
Debt Instrument [Line Items]
Purchase common stock with warrant issue | shares					348,664
Warrant, exercise price per share | $ / shares			$ 1.73		$ 1.73
Warrants, exercisable date					Nov. 17, 2024
Athyrium Opportunities I I I Acquisition Limited Partnership Credit Agreement [Member]
Debt Instrument [Line Items]
Reduction in principal amount of debt	$ 16,000
Debt instrument, maturity date			Dec. 31, 2023		Dec. 31, 2023
Reduction in stated interest rate					0.015
Settlement of accrued exit fees					$ 160
Settlement of accrued exit fees in exchange for cash					10,100
Settlement of accrued exit fees in exchange for value					$ 9,271
Settlement of accrued exit fees in exchange for shares | shares					2,202,420
Fee for updated letter					$ 500
Principal balance and accrued exit fee					$ 6,060
Debt maturity date, description					an extension of the maturity date of the term loans from March 31, 2023 to December 31, 2023
Debt instrument exit fee			$ 1,000		$ 1,000
Term loan interest rate, description					interest equal to the three-month LIBOR rate, with a 1% floor plus 8.25% per annum
Exit fee percentage								1.00%
Debt instrument, covenant description					The Credit Agreement contains certain usual and customary affirmative and negative covenants, as well as financial covenants that the Company will need to satisfy on a monthly and quarterly basis, including maintaining a permitted net leverage ratio (which is the Company’s indebtedness under the Credit Agreement, net of cash and cash equivalents, divided by EBITDA, each as defined in the Credit Agreement) and liquidity amount. As of September 30, 2021, the Company was in compliance with its covenants under the Credit Agreement.
Debt instrument, early repayment terms					if the Company makes any prepayments prior to maturity, the Company would be subject to the following prepayment premiums as a percentage of the amount repaid: (i) term A loans at 2.5% through March 31, 2022 with no penalty thereafter; and (ii) term B loans at 5.0% through March 31, 2022 and 2.5% thereafter.
Athyrium Opportunities I I I Acquisition Limited Partnership Credit Agreement [Member] | Floor [Member]
Debt Instrument [Line Items]
Term loan variable interest rate					1.00%
Athyrium Opportunities I I I Acquisition Limited Partnership Credit Agreement [Member] | LIBOR [Member]
Debt Instrument [Line Items]
Term loan variable interest rate					8.25%
Athyrium Second Amendment Credit Agreement [Member]
Debt Instrument [Line Items]
Effective interest rate			13.80%		13.80%
Note With Former Member of IriSys [Member]
Debt Instrument [Line Items]
Debt instrument, maturity date			Aug. 13, 2024		Aug. 13, 2024
Carrying value of debt			$ 6,117		$ 6,117
Debt Instrument, Interest Rate, Stated Percentage			6.00%		6.00%
Long-term debt term			3 years		3 years
Accrued Interest			$ 49		$ 49
Unamortized original discount			877		$ 877
Debt Instrument, Interest Rate, Basis for Effective Rate					13.0
Others [Member]
Debt Instrument [Line Items]
Debt principal			415		$ 415
Term Loans Under Credit Agreement [Member]
Debt Instrument [Line Items]
Debt principal			100,000		100,000		$ 116,000
Debt instrument, exit fee			627		627
Non-cash interest expense			1,389	$ 1,303	4,469	$ 4,222
Paycheck Protectiion Program [Member]
Debt Instrument [Line Items]
Debt instrument, face amount		$ 4,416
Debt Instrument, Interest Rate, Stated Percentage		1.00%
Long-term debt term		2 years
Repayments of Long-term Debt		$ 1,100
Gain on extinguishment of debt					3,352
Debt forgiveness					3,316
Accrued interest					36
A Term Loan [Member]
Debt Instrument [Line Items]
Credit agreement			48,000		$ 48,000
Debt instrument early repayment of prepayment penalty percentage					2.50%
B Term Loan [Member]
Debt Instrument [Line Items]
Credit agreement			$ 52,000		$ 52,000
Debt instrument early repayment of prepayment penalty percentage					5.00%
Debt instrument minimum prepayment penalty percentage thereafter					2.50%

Stockholders Equity or Deficit

Stockholders Equity or Deficit - Summary of Capital Raises Since its Initial Public Offreing (Detail) - USD ($) $ in Thousands	May 12, 2021	Dec. 16, 2016	Aug. 19, 2016	Jul. 07, 2015	Mar. 12, 2014	Dec. 31, 2018	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2020
Schedule Of Capitalization Equity [Line Items]
Issuance of common stock, net of costs							$ 20,328	$ 32,103	$ 9,340
Initial Public Offering [Member]
Schedule Of Capitalization Equity [Line Items]
Issuance of common stock, net of costs, Shares					4,312,500
Gross proceeds on sale of common stock in initial public offering					$ 34,500
Payments on underwriting discounts, commissions and offering costs					(4,244)
Issuance of common stock, net of costs					$ 30,256
Private Placement [Member]
Schedule Of Capitalization Equity [Line Items]
Issuance of common stock, net of costs, Shares				1,379,311
Gross proceeds on sale of common stock in initial public offering				$ 16,000
Payments on underwriting discounts, commissions and offering costs				(1,188)
Issuance of common stock, net of costs				$ 14,812
Underwriters Public Offering [Member]
Schedule Of Capitalization Equity [Line Items]
Issuance of common stock, net of costs, Shares	15,333,332	6,670,000	1,986,666
Gross proceeds on sale of common stock in initial public offering	$ 34,500	$ 40,020	$ 14,900
Payments on underwriting discounts, commissions and offering costs	(2,397)	(3,132)	(1,533)
Issuance of common stock, net of costs	$ 32,103	$ 36,888	$ 13,367
2018 Common Stock Purchase Agreement [Member]
Schedule Of Capitalization Equity [Line Items]
Issuance of common stock, net of costs, Shares						1,950,000
Gross proceeds on sale of common stock in initial public offering						$ 16,999
Issuance of common stock, net of costs						$ 16,999
2019 Common Stock Purchase Agreement [Member]
Schedule Of Capitalization Equity [Line Items]
Issuance of common stock, net of costs, Shares										4,690,972
Gross proceeds on sale of common stock in initial public offering										$ 11,172
Payments on underwriting discounts, commissions and offering costs										(78)
Issuance of common stock, net of costs										$ 11,094

Stockholders Equity or Defici_2

Stockholders Equity or Deficit - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	Aug. 13, 2021	Feb. 13, 2021	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2021	Sep. 30, 2021
Common Stock [Member]
Schedule Of Capitalization Equity [Line Items]
Issuance of common stock, net of costs, Shares			15,333,332	2,202,420
Warrants, Exercise Price $6.84, Expiring on November 2024 [Member] | Equity [Member] | Athyrium Opportunities II Acquisition LP [Member]
Schedule Of Capitalization Equity [Line Items]
Warrants outstanding to purchase shares, Number of Shares						348,664
Warrant, exercise price per share						$ 1.73
Warrants outstanding to purchase shares, Expiration dates						2024-11
Irisys LLC [Member]
Schedule Of Capitalization Equity [Line Items]
Number of share issued for acquisition	9,302,718	9,302,718
Business acquisition transaction costs	$ 1,211	$ 600
Irisys LLC [Member] | Forward Contracts [Member]
Schedule Of Capitalization Equity [Line Items]
Fair value of forward contract		$ 20,931
Aspire Capital
Schedule Of Capitalization Equity [Line Items]
Purchase commitment of common stock, Shares						41,172
Aspire Capital | Minimum [Member]
Schedule Of Capitalization Equity [Line Items]
Issuance of common stock, net of costs, Shares					30,000
Aspire Capital | Maximum [Member]
Schedule Of Capitalization Equity [Line Items]
Issuance of common stock, net of costs, Shares					6,199,299

Revenue Recognition - Schedule

Revenue Recognition - Schedule of Changes in Contract Assets and Liabilities (Detail) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Contract with Customer Asset
Balance at December 31, 2020	$ 7,330
Changes to the beginning balance of contract assets arising from:
Reclassification to receivables as a result of rights to consideration becoming unconditional	(8,774)
Changes in estimate	1,508
Acquisition of IriSys	505
Contract assets recognized since beginning of period, net of reclassification to receivables and changes in estimates	6,745
Balance at September 30, 2021	7,314
Less: noncurrent portion	0
Current portion	7,314	$ 7,330
Contract with Customer, Liability
Balance at December 31, 2020	2,695
Changes to contract liabilities:
Amounts billed in advance of contract performance	4,097
Revenue recognized	(4,391)
Acquisition of IriSys	930
Balance at September 30, 2021	3,331
Less: noncurrent portion	(1,015)
Current portion	$ 2,316	$ 1,447

Revenue Recognition - Disaggreg

Revenue Recognition - Disaggregation of Revenue by Timing of Revenue Recognition (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Disaggregation Of Revenue [Line Items]
Revenue	$ 18,237	$ 19,287	$ 53,057	$ 56,586
Point In Time [Member]
Disaggregation Of Revenue [Line Items]
Revenue	14,361	17,827	45,947	53,247
Over Time [Member]
Disaggregation Of Revenue [Line Items]
Revenue	$ 3,876	$ 1,460	$ 7,110	$ 3,339

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended				9 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Sep. 30, 2021	Sep. 30, 2020
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options exercisable period					10 years
Stock options vest period					4 years
Intrinsic value of options exercised						$ 1,058
Stock Options Granted Outside Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of options, Granted					903,542
Restricted Stock Units [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares. Granted					743,956
Weighted average grant-date fair value of the RSU's awarded to employees					$ 3.49	$ 15.11
Fair value vested					$ 1,868	$ 3,246
Restricted Stock Units [Member] | Minimum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options vest period					6 months
Restricted Stock Units [Member] | Maximum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options vest period					4 years
Stock Options and Time Based Restricted Stock Units [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unrecognized compensation expense related to unvested options and time-based RSUs, expected to vest					$ 8,232
Unrecognized compensation expense related to unvested options, weighted average period					2 years 6 months
Time Based Restricted Stock Units [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares. Granted					232,822
A&R Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of outstanding common stock		5.00%	5.00%	5.00%
Shares available for future grants					2,431,418
A&R Plan [Member] | Forecast [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of outstanding common stock	5.00%

Stock-Based Compensation - Fair

Stock-Based Compensation - Fair Value of Stock Options Granted (Detail) - $ / shares	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares, Granted	$ 1.78	$ 8.24
Assumptions used to determine fair value:
Expected dividend yield	0.00%	0.00%
Minimum [Member]
Assumptions used to determine fair value:
Range of expected option life	5 years 6 months	5 years 6 months
Expected volatility	79.00%	75.00%
Risk-free interest rate	0.70%	0.30%
Maximum [Member]
Assumptions used to determine fair value:
Range of expected option life	6 years	6 years
Expected volatility	81.00%	81.00%
Risk-free interest rate	1.20%	1.40%

Stock-Based Compensation - Summ

Stock-Based Compensation - Summary of Stock Option Activity (Detail) - USD ($) $ / shares in Units, $ in Thousands	9 Months Ended
	Sep. 30, 2021
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Number of shares, Beginning balance	3,907,010
Number of shares, Granted	1,575,534
Number of shares, Exercised	(80)
Number of shares, Forfeited or expired	(185,172)
Number of shares, Ending balance	5,297,292
Number of shares, Exercisable	3,268,854
Weighted average exercise price, Beginning balance	$ 8.03
Weighted average exercise price, Granted	2.64
Weighted average exercise price, Exercised	2.31
Weighted average exercise price, Forfeited or expired	6.48
Weighted average exercise price, Ending balance	6.48
Weighted average exercise price, Exercisable	$ 8.05
Weighted average remaining contractual life	6 years
Weighted average remaining contractual life, Exercisable	3 years 10 months 24 days
Aggregate intrinsic value	$ 1

Stock-Based Compensation - Su_2

Stock-Based Compensation - Summary of Restricted Stock Units Activity (Detail) - $ / shares	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares, Granted	$ 1.78	$ 8.24
Restricted Stock Units [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares, Beginning balance	1,516,819
Number of shares. Granted	743,956
Number of shares, Vested	(680,194)
Number of shares, Forfeited	(106,408)
Number of shares, Ending balance	1,474,173
Number of shares, beginning balance	$ 5.67
Number of shares, Granted	3.49
Number of shares, Vested	7.89
Number of shares, Forfeited	9.26
Number of shares, ending balance	$ 3.29

Stock-Based Compensation - Su_3

Stock-Based Compensation - Summary of Stock Based Compensation Expenses (Detail) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock based compensation expense	$ 6,381	$ 8,086
Cost of Sales [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock based compensation expense	3,081	2,293
Selling, General and Administrative Expenses [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock based compensation expense	$ 3,300	$ 5,793

Fair Value of Financial Instr_2

Fair Value of Financial Instruments - Additional Information (Detail) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Money Market Mutual Funds [Member] | Quoted Prices in Active Markets for Identical Assets (Level 1) [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Cash equivalents	$ 15,411	$ 6,583

Leases - Additional Information

Leases - Additional Information (Detail) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021USD ($)	Sep. 30, 2020USD ($)	Sep. 30, 2021USD ($)Lease	Sep. 30, 2020USD ($)
Lessee Lease Description [Line Items]
Number of operating lease			2
Number of development lease			2
Operating lease, weighted average remaining term	8 years 10 months 24 days		8 years 10 months 24 days
Operating lease, weighted average discount rate percent	14.20%		14.20%
Total operating lease, cost | $	$ 161	$ 76	$ 347	$ 234
Georgia [Member]
Lessee Lease Description [Line Items]
Operating lease, option to extend			The development facility leases each include options to extend, none of which are included in the lease terms.
Operating lease expiration year			2025
California [Member]
Lessee Lease Description [Line Items]
Operating lease, option to extend			The development facility leases each include options to extend, none of which are included in the lease terms.
Operating lease expiration year			2031

Leases - Schedule of Undiscount

Leases - Schedule of Undiscounted Future Lease Payments for the Development Lease (Detail) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Lessee Lease Description [Line Items]
2022	$ 1,158
2023	1,186
2024	1,189
2025	1,089
2026	5,086
Thereafter	10,838
Total lease payments	4,842
Less imputed interest	(5,996)
Operating lease liability	$ 1,049	$ 145